In January, we achieved the first preclinical milestone under our collaboration with Boehringer Ingelheim.
In February, RBD2080 received the approval to initiate its phase 1 clinical trial in Australia.
In February, we completed patient enrollment for RBD4059’s phase 2a clinical trial in patients with coronary artery disease in Sweden.
In January, RBD1016’s phase 2 global MRCT in CHB patients expanded to Hong Kong.
In April, RBD4059’s phase 1 clinical trial in Australia was completed.
In August, RBD1016’s phase 2a clinical trial in CHD patients was initiated in Sweden.
In August, RBD4059’s phase 2a clinical trial in patients with coronary artery disease in Sweden was initiated.
In September, RBD7007 received CTA approval from EMA to initiate its phase 1 clinical trial.
In March, RBD4059’s phase 1 clinical trial in Australia was initiated.
In August, RBD1016’s phase 2 global MRCT in CHB patients was initiated in Sweden.
In October, we completed RBD1016’s phase 1b clinical trial in patients with CHB in Hong Kong.
In December, we entered into a license and collaboration agreement with Qilu Pharmaceutical, pursuant to which we granted Qilu Pharmaceutical a license to develop, manufacture, and commercialize RBD7022 in mainland China, Hong Kong and Macau.
In December, we entered into a strategic partnership with Boehringer Ingelheim to jointly progress potential first-in-class siRNAs utilizing our RiboGalSTARTM technology.
In February, we established Ribocure AB in Sweden as our international R&D center.
In September, we completed Series E1 Financing and raised RMB254.00 million.
In November, we completed RBD1016’s phase 1a clinical trial in Australia.
In April, we completed Series C2 Financing and raised RMB454 million.
In September, we completed Series C+ Financing and raised RMB250.0 million.
In December, we completed Series C1 Financing and raised RMB203.1 million.
In February, we completed Series B Financing.
In September, we completed Series A Financing.
In December, RBD1007 received IND approval from NMPA, marking the first oligonucleotide drug approved to enter clinical stage in China.
In December, we completed ISO 9001:2008 quality management system accreditation.
In April, we successfully hosted the first RNAi China conference.
In January, our Company was established as a limited liability company in Kunshan, Jiangsu Province.
In April, our R&D center was established in Zhongguancun, Beijing.
